+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia Pacific Small Molecule API Market 2020-2027 by Source (Synthetic, Semi-synthetic, Natural), Type (Standard, HPAPI), Therapeutic Area, Application (Clinical, Commercial), Manufacturer Type (Pharma, CMO), and Country: Trend Forecast and Growth Opportunity

  • PDF Icon

    Report

  • 112 Pages
  • April 2021
  • Region: Asia Pacific
  • GMD Research
  • ID: 5319172

Asia Pacific small molecule active pharmaceutical ingredient (API) market will grow by 9.2% annually with a total addressable market cap of $537.3 billion over 2021-2027 owing to increasing incidences of diseases, development of companies engaged in the manufacturing of small molecule APIs, the increasing technological developments in manufacturing sector, and surge in healthcare expenditure amid COVID-19 pandemic.



Highlighted with 33 tables and 52 figures, this 112-page report “Asia Pacific Small Molecule API Market 2020-2027 by Source (Synthetic, Semi-synthetic, Natural), Type (Standard, HPAPI), Therapeutic Area, Application (Clinical, Commercial), Manufacturer Type (Pharma, CMO), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific small molecule API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year because 2020 is not appropriate for research base due to the outbreak of COVID-19.



In-depth qualitative analyses include identification and investigation of the following aspects:

  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Five Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific small molecule API market in every aspect of the classification from perspectives of Source, Type, Therapeutic Area, Application, Manufacturer Type, and Country.



Based on Source, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.

  • Synthetic API
  • Branded Synthetic API
  • Generic Synthetic API
  • Semi-synthetic API
  • Natural Origin

Based on Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.

  • Standard API
  • High Potency API (HPAPI)
  • Branded HPAPI
  • Generic HPAPI

Based on Therapeutic Area, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.

  • Infectious Diseases
  • Oncology
  • Ophthalmology
  • Cardiovascular Disorders
  • Central Nervous System
  • Respiratory Disorders
  • Metabolic Diseases
  • Other Applications

Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.

  • Clinical Use
  • Commercial Use

Based on Manufacturer Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.

  • Pharmaceutical Companies
  • CMOs

Geographically, the following national/local markets are fully investigated:

  • Japan
  • China
  • South Korea
  • Australia
  • India
  • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2017-2027. The breakdown of key national markets by Type, Therapeutic Area, and Manufacturer Type over the forecast years are also included.



The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.



Key Players (this may not be a complete list and extra companies can be added upon request):

  • Aurobindo Pharma Ltd.
  • Cambrex Corporation
  • Catalent, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Lonza Group
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Wuxi AppTec Co., Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)


Frequently Asked Questions about the Asian Pacific Small Molecule API Market

What is the estimated value of the Asian Pacific Small Molecule API Market?

The Asian Pacific Small Molecule API Market was estimated to be valued at $52670 Million in 2020.

What is the growth rate of the Asian Pacific Small Molecule API Market?

The growth rate of the Asian Pacific Small Molecule API Market is 9.2%, with an estimated value of $97380 Million by 2027.

What is the forecasted size of the Asian Pacific Small Molecule API Market?

The Asian Pacific Small Molecule API Market is estimated to be worth $97380 Million by 2027.

Who are the key companies in the Asian Pacific Small Molecule API Market?

Key companies in the Asian Pacific Small Molecule API Market include Aurobindo Pharma Ltd., Cambrex Corporation, Catalent, Inc., Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Lonza Group, Merck & Co., Inc., Mylan N.V., Novartis AG and Pfizer Inc..

Table of Contents

1 Introduction
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary

2 Market Overview and Dynamics
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on World Economy
2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Five Forces Analysis

3 Segmentation of Asia Pacific Market by Source
3.1 Market Overview by Source
3.2 Synthetic API
3.2.1 Branded Synthetic API
3.2.2 Generic Synthetic API
3.3 Semi-synthetic API
3.4 Natural Origin

4 Segmentation of Asia Pacific Market by Type
4.1 Market Overview by Type
4.2 Standard API
4.3 High Potency API (HPAPI)
4.3.1 Branded HPAPI
4.3.2 Generic HPAPI

5 Segmentation of Asia Pacific Market by Therapeutic Area
5.1 Market Overview by Therapeutic Area
5.2 Infectious Diseases
5.3 Oncology
5.4 Ophthalmology
5.5 Cardiovascular Disorders
5.6 Central Nervous System
5.7 Respiratory Disorders
5.8 Metabolic Diseases
5.9 Other Applications

6 Segmentation of Asia Pacific Market by Application
6.1 Market Overview by Application
6.2 Clinical Use
6.3 Commercial Use

7 Segmentation of Asia Pacific Market by Manufacturer Type
7.1 Market Overview by Manufacturer Type
7.2 Pharmaceutical Companies
7.3 CMOs

8 Asia-Pacific Market 2020-2027 by Country
8.1 Overview of Asia-Pacific Market
8.2 China
8.3 Japan
8.4 India
8.5 Australia
8.6 South Korea
8.7 Rest of APAC Region

9 Competitive Landscape
9.1 Overview of Key Vendors
9.2 New Product Launch, Partnership, Investment, and M&A
9.3 Company Profiles
  • Aurobindo Pharma Ltd.
  • Cambrex Corporation
  • Catalent, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Lonza Group
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Wuxi AppTec Co., Ltd.

10 Investing in Asia Pacific Market: Risk Assessment and Management
10.1 Risk Evaluation of Asia Pacific Market
10.2 Critical Success Factors (CSFs)List of Tables
Table 1. Snapshot of Asia Pacific Small Molecule API Market in Balanced Perspective, 2020-2027
Table 2. Growth Rate of World GDP, 2020-2022
Table 3. Main Product Trends and Market Opportunities in Asia Pacific Small Molecule API Market
Table 4. Asia Pacific Small Molecule API Market by Source, 2017-2027, $ mn
Table 5. Asia Pacific Small Molecule API Market: Synthetic API by Drug Type, 2017-2027, $ mn
Table 6. Asia Pacific Small Molecule API Market by Type, 2017-2027, $ mn
Table 7. Asia Pacific Small Molecule API Market: HPAPI by Drug Type, 2017-2027, $ mn
Table 8. Asia Pacific Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn
Table 9. Asia Pacific Small Molecule API Market by Application, 2017-2027, $ mn
Table 10. Asia Pacific Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn
Table 11. APAC Small Molecule API Market by Country, 2017-2027, $ mn
Table 12. China Small Molecule API Market by Type, 2017-2027, $ mn
Table 13. China Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn
Table 14. China Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn
Table 15. Japan Small Molecule API Market by Type, 2017-2027, $ mn
Table 16. Japan Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn
Table 17. Japan Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn
Table 18. India Small Molecule API Market by Type, 2017-2027, $ mn
Table 19. India Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn
Table 20. India Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn
Table 21. Australia Small Molecule API Market by Type, 2017-2027, $ mn
Table 22. Australia Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn
Table 23. Australia Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn
Table 24. South Korea Small Molecule API Market by Type, 2017-2027, $ mn
Table 25. South Korea Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn
Table 26. South Korea Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn
Table 27. Small Molecule API Market in Rest of APAC by Country/Region, 2017-2027, $ mn
Table 28. Aurobindo Pharma Ltd.: Company Snapshot
Table 29. Aurobindo Pharma Ltd.: Business Segmentation
Table 30. Aurobindo Pharma Ltd.: Product Portfolio
Table 31. Aurobindo Pharma Ltd.: Revenue, 2017-2019, $ mn
Table 32. Risk Evaluation for Investing in Asia Pacific Market, 2020-2027
Table 33. Critical Success Factors and Key TakeawaysList of Figures
Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027
Figure 5. Asia Pacific Small Molecule API Market, 2017-2027, $ mn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Small Molecule API Market
Figure 8. Primary Restraints and Impact Factors of Asia Pacific Small Molecule API Market
Figure 9. Investment Opportunity Analysis
Figure 10. Porter’s Five Forces Analysis of Asia Pacific Small Molecule API Market
Figure 11. Breakdown of Asia Pacific Small Molecule API Market by Source, 2020-2027, % of Revenue
Figure 12. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Source, Value ($ mn) and Share (%)
Figure 13. Asia Pacific Small Molecule API Market: Synthetic API, 2017-2027, $ mn
Figure 14. Asia Pacific Small Molecule API Market: Branded Synthetic API, 2017-2027, $ mn
Figure 15. Asia Pacific Small Molecule API Market: Generic Synthetic API, 2017-2027, $ mn
Figure 16. Asia Pacific Small Molecule API Market: Semi-synthetic API, 2017-2027, $ mn
Figure 17. Asia Pacific Small Molecule API Market: Natural Origin, 2017-2027, $ mn
Figure 18. Breakdown of Asia Pacific Small Molecule API Market by Type, 2020-2027, % of Revenue
Figure 19. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Type, Value ($ mn) and Share (%)
Figure 20. Asia Pacific Small Molecule API Market: Standard API, 2017-2027, $ mn
Figure 21. Asia Pacific Small Molecule API Market: High Potency API (HPAPI), 2017-2027, $ mn
Figure 22. Asia Pacific Small Molecule API Market: Branded HPAPI, 2017-2027, $ mn
Figure 23. Asia Pacific Small Molecule API Market: Generic HPAPI, 2017-2027, $ mn
Figure 24. Breakdown of Asia Pacific Small Molecule API Market by Therapeutic Area, 2020-2027, % of Revenue
Figure 25. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Therapeutic Area, Value ($ mn) and Share (%)
Figure 26. Asia Pacific Small Molecule API Market: Infectious Diseases, 2017-2027, $ mn
Figure 27. Asia Pacific Small Molecule API Market: Oncology, 2017-2027, $ mn
Figure 28. Asia Pacific Small Molecule API Market: Ophthalmology , 2017-2027, $ mn
Figure 29. Asia Pacific Small Molecule API Market: Cardiovascular Disorders, 2017-2027, $ mn
Figure 30. Asia Pacific Small Molecule API Market: Central Nervous System, 2017-2027, $ mn
Figure 31. Asia Pacific Small Molecule API Market: Respiratory Disorders, 2017-2027, $ mn
Figure 32. Asia Pacific Small Molecule API Market: Metabolic Diseases, 2017-2027, $ mn
Figure 33. Asia Pacific Small Molecule API Market: Other Applications, 2017-2027, $ mn
Figure 34. Breakdown of Asia Pacific Small Molecule API Market by Application, 2020-2027, % of Revenue
Figure 35. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Application, Value ($ mn) and Share (%)
Figure 36. Asia Pacific Small Molecule API Market: Clinical Use, 2017-2027, $ mn
Figure 37. Asia Pacific Small Molecule API Market: Commercial Use, 2017-2027, $ mn
Figure 38. Breakdown of Asia Pacific Small Molecule API Market by Manufacturer Type, 2020-2027, % of Revenue
Figure 39. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Manufacturer Type, Value ($ mn) and Share (%)
Figure 40. Asia Pacific Small Molecule API Market: Pharmaceutical Companies, 2017-2027, $ mn
Figure 41. Breakdown of Asia Pacific Small Molecule API In-house Synthesis Market by Region, 2020-2027, % of Revenue
Figure 42. Asia Pacific Small Molecule API Market: CMOs, 2017-2027, $ mn
Figure 43. Breakdown of Asia Pacific Small Molecule API Contract Synthesis Market by Region, 2020-2027, % of Revenue
Figure 44. Breakdown of APAC Small Molecule API Market by Country, 2020 and 2027, % of Revenue
Figure 45. Contribution to APAC 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 46. Small Molecule API Market in China, 2017-2027, $ mn
Figure 47. Small Molecule API Market in Japan, 2017-2027, $ mn
Figure 48. Small Molecule API Market in India, 2017-2027, $ mn
Figure 49. Small Molecule API Market in Australia, 2017-2027, $ mn
Figure 50. Small Molecule API Market in South Korea, 2017-2027, $ mn
Figure 51. Small Molecule API Market in Rest of APAC, 2017-2027, $ mn
Figure 52. Growth Stage of Asia Pacific Small Molecule API Industry over the Forecast Period

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Aurobindo Pharma Ltd.
  • Cambrex Corporation
  • Catalent, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Lonza Group
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Wuxi AppTec Co., Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Methodology

Loading
LOADING...